Reckitt Benckiser Group To Pay $1.4 Billion To Resolve Federal Investigation of Opioid Treatment Marketing

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Reckitt Benckiser Group To Pay $1.4 Billion To Resolve Federal Investigation of Opioid Treatment Marketing

J.W. Schomisch

July 13, 2019 at 02:48 PM EST

Reckitt Benckiser Group plc (RB Group) agreed to pay $1.4 billion to resolve potential criminal and civil liability related to a federal investigation of the marketing of its opioid addiction treatment drug Suboxone. “While RB has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct, after careful consideration, the Board of... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Reckitt Benckiser Group To Pay $1.4 Billion To Resolve Federal Investigation of Opioid Treatment Marketing

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT